| Literature DB >> 36230349 |
Marefa Jahan1,2, Cara Wilson1,2,3, Shawn McGrath1,2, Nidhish Francis2, Peter C Wynn1, Yuguang Du4, Bruce Allworth1,2,3, Bing Wang1,2.
Abstract
Chitosan oligosaccharide (COS) is derived through deacetylation of chitin from crustacean shells. Previous studies reported the benefits of COS to gut microbiota, immunity and health of host species. In this study, 120 pregnant composite ewes were subdivided into treatment and control groups in duplicate. COS was supplemented via a loose lick to provide an estimated intake of COS @100-600 mg/d/ewe for five weeks pre-lambing until lamb marking. Body weight was recorded pre-treatment for ewes, and at lamb marking and weaning for both ewes and lambs. Serum immunity markers immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), secretory immunoglobulin A (sIgA), interleukin (IL)-2, IL10 and faecal sIgA were determined for ewes and lambs at lamb marking and weaning by enzyme-linked immunosorbent assay (ELISA). We found that COS can be incorporated in sheep feed without compromising palatability. Maternal COS supplementation did not influence the body weight of ewes or lambs. It did, however, significantly increase the concentrations of serum IL2 in ewes at marking and weaning (p < 0.001). In lambs, COS also significantly increased the IL2 concentration at making (p = 0.018) and weaning (p = 0.029) and serum IgM at marking (p < 0.001). No significant effect was observed in the concentration of any other immune marker or cytokine in either ewes or lambs. In conclusion, maternal COS supplementation significantly modulated some immunity markers in both ewes and lambs. The short duration of maternal COS supplementation and optimal seasonal conditions during the trial may explain the lack of significant body weight in ewes and lambs from the COS supplementation.Entities:
Keywords: Chitosan oligosaccharide; body weight; ewe; immunity; lamb
Year: 2022 PMID: 36230349 PMCID: PMC9558557 DOI: 10.3390/ani12192609
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Figure 1Experimental schedule of COS supplementation.
Figure 2Loose lick intake between the treatment and control ewes. (A) Overall mean loose lick intake between the treatment and control ewes from the commencement of the trial until marking (B) Average loose lick intake at pre-lambing (2nd and 6th week) and lambing to marking (8th and 11th week) after the commencement of the trial (C). Average loose lick intake of each replicate of treatment and control group at pre-lambing 2nd and 4th week and lambing to marking 6th and 11th week after the commencement of the trial.
Figure 3Body weight of ewes and lambs. (A) Mean (±standard error, SE) body weight of the treatment and control ewes from trial commencement to weaning (B) Mean (±SE) body weight of the treatment and control lambs measured at marking and weaning.
Figure 4Concentration (mean ± SE) of serum immunity markers in ewes for treatment and control groups at marking. (A) Concentration of serum IgM, IgG, sIgA, (B). Concentration of serum IL (interleukin) 2 and IL10. * p = 0.000.
Figure 5Concentration (mean ± SE) of serum immunity markers in lambs for the treatment and control groups at marking. (A) Concentration of IgM, IgG, sIgA (B) Concentration of IL (interleukin) 2 and IL10. * p = 0.000 and p = 0.018 for IgM and IL2, respectively.
Figure 6Concentration (mean ± SE) of secretory IgA (sIgA) in faeces of ewes and lambs at marking.
Figure 7Concentration (mean ± SE) of serum immunity markers in ewes for control and treatment groups at weaning. (A) Concentration of IgM, IgG, sIgA (B) Concentration of serum IL (interleukin) 2 and IL10. * p = 0.000.
Figure 8Concentrations of immunity weaning in the lamb serum samples of COS treatment and control groups of lambs collected at weaning day. (A) Concentration of IgM, IgG, sIgA (B) Concentration of IL (interleukin) 2 and IL10. Values are mean ± SE. * p = 0.029.